2,415 Shares in Cencora, Inc. (NYSE:COR) Purchased by Bryce Point Capital LLC

Bryce Point Capital LLC purchased a new stake in Cencora, Inc. (NYSE:COR) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 2,415 shares of the company’s stock, valued at approximately $543,000.

A number of other large investors have also recently modified their holdings of the business. Meeder Advisory Services Inc. increased its position in shares of Cencora by 4.1% in the fourth quarter. Meeder Advisory Services Inc. now owns 4,058 shares of the company’s stock worth $912,000 after purchasing an additional 159 shares during the last quarter. Geode Capital Management LLC grew its stake in Cencora by 3.1% in the 4th quarter. Geode Capital Management LLC now owns 4,326,064 shares of the company’s stock worth $969,471,000 after buying an additional 130,213 shares in the last quarter. HighPoint Advisor Group LLC increased its holdings in shares of Cencora by 4.2% in the 4th quarter. HighPoint Advisor Group LLC now owns 5,299 shares of the company’s stock worth $1,307,000 after buying an additional 215 shares during the last quarter. Franklin Resources Inc. raised its position in shares of Cencora by 1.9% during the 4th quarter. Franklin Resources Inc. now owns 211,076 shares of the company’s stock valued at $47,425,000 after buying an additional 3,945 shares in the last quarter. Finally, B. Metzler seel. Sohn & Co. AG raised its position in shares of Cencora by 0.9% during the 4th quarter. B. Metzler seel. Sohn & Co. AG now owns 7,389 shares of the company’s stock valued at $1,660,000 after buying an additional 69 shares in the last quarter. Institutional investors own 97.52% of the company’s stock.

Insider Transactions at Cencora

In related news, Chairman Steven H. Collis sold 14,578 shares of the company’s stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $269.51, for a total transaction of $3,928,916.78. Following the completion of the transaction, the chairman now owns 317,913 shares in the company, valued at $85,680,732.63. This represents a 4.38 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Elizabeth S. Campbell sold 4,127 shares of the firm’s stock in a transaction on Monday, March 24th. The stock was sold at an average price of $268.28, for a total value of $1,107,191.56. Following the completion of the sale, the executive vice president now directly owns 14,665 shares of the company’s stock, valued at $3,934,326.20. The trade was a 21.96 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 30,675 shares of company stock worth $8,034,778. Company insiders own 10.80% of the company’s stock.

Cencora Price Performance

Shares of Cencora stock opened at $289.41 on Friday. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. Cencora, Inc. has a one year low of $214.77 and a one year high of $291.83. The business’s 50 day simple moving average is $256.66 and its two-hundred day simple moving average is $242.38. The stock has a market capitalization of $56.12 billion, a P/E ratio of 41.17, a price-to-earnings-growth ratio of 1.31 and a beta of 0.51.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. Analysts forecast that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were paid a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 0.76%. The ex-dividend date was Friday, February 14th. Cencora’s dividend payout ratio (DPR) is 31.29%.

Wall Street Analyst Weigh In

A number of research analysts recently commented on COR shares. Evercore ISI increased their target price on Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a research note on Thursday, February 6th. StockNews.com upgraded Cencora from a “hold” rating to a “buy” rating in a report on Wednesday, March 12th. JPMorgan Chase & Co. raised their price objective on Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a report on Friday, January 24th. Finally, Wells Fargo & Company upped their target price on Cencora from $251.00 to $274.00 and gave the stock an “equal weight” rating in a research note on Friday, March 14th. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, Cencora presently has an average rating of “Moderate Buy” and a consensus price target of $280.20.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.